Literature DB >> 18827378

Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors.

Qingang Yang1, Lili Chen, Xuchang He, Zhenting Gao, Xu Shen, Donglu Bai.   

Abstract

The severe acute respiratory syndrome (SARS) coronavirus 3CL protease is an attractive target for the development of anti-SARS drugs. In this paper, cinanserin (1) analogs were synthesized and tested for the inhibitory activities against SARS-coronavirus (CoV) 3CL protease by fluorescence resonance energy transfer (FRET) assay. Four analogs show significant activities, especially compound 26 with an IC(50) of 1.06 microM.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18827378     DOI： 10.1248/cpb.56.1400

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN： 0009-2363            Impact factor:   1.645


  12 in total

1.  Inhibitors of SARS-3CLpro: virtual screening, biological evaluation, and molecular dynamics simulation studies.

Authors:  Prasenjit Mukherjee; Falgun Shah; Prashant Desai; Mitchell Avery
Journal:  J Chem Inf Model       Date:  2011-05-23       Impact factor: 4.956

Review 2.  Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses.

Authors:  Peter Riederer; Volker Ter Meulen
Journal:  J Neural Transm (Vienna)       Date:  2020-07-28       Impact factor: 3.575

Review 3.  Evaluation of antiviral activities of Houttuynia cordata Thunb. extract, quercetin, quercetrin and cinanserin on murine coronavirus and dengue virus infection.

Authors:  K H Chiow; M C Phoon; Thomas Putti; Benny K H Tan; Vincent T Chow
Journal:  Asian Pac J Trop Med       Date:  2015-12-19       Impact factor: 1.226

4.  Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors.

Authors:  R Ramajayam; Kian-Pin Tan; Hun-Ge Liu; Po-Huang Liang
Journal:  Bioorg Med Chem       Date:  2010-09-25       Impact factor: 3.641

5.  Artificial intelligence approach fighting COVID-19 with repurposing drugs.

Authors:  Yi-Yu Ke; Tzu-Ting Peng; Teng-Kuang Yeh; Wen-Zheng Huang; Shao-En Chang; Szu-Huei Wu; Hui-Chen Hung; Tsu-An Hsu; Shiow-Ju Lee; Jeng-Shin Song; Wen-Hsing Lin; Tung-Jung Chiang; Jiunn-Horng Lin; Huey-Kang Sytwu; Chiung-Tong Chen
Journal:  Biomed J       Date:  2020-05-15       Impact factor: 4.910

6.  Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease.

Authors:  Hiroyuki Konno; Masaki Wakabayashi; Daiki Takanuma; Yota Saito; Kenichi Akaji
Journal:  Bioorg Med Chem       Date:  2016-01-29       Impact factor: 3.641

7.  Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease.

Authors:  R Ramajayam; Kian-Pin Tan; Hun-Ge Liu; Po-Huang Liang
Journal:  Bioorg Med Chem Lett       Date:  2010-05-20       Impact factor: 2.823

8.  In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease.

Authors:  Tien Huynh; Haoran Wang; Binquan Luan
Journal:  J Phys Chem Lett       Date:  2020-05-21       Impact factor: 6.475

Review 9.  Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors.

Authors:  Abhik Paul; Arnab Sarkar; Sanjukta Saha; Avik Maji; Pritha Janah; Tapan Kumar Maity
Journal:  Bioorg Med Chem       Date:  2021-07-03       Impact factor: 3.641

10.  Discovery of novel GPVI receptor antagonists by structure-based repurposing.

Authors:  Lewis Taylor; Sridhar R Vasudevan; Chris I Jones; Jonathan M Gibbins; Grant C Churchill; R Duncan Campbell; Carmen H Coxon
Journal:  PLoS One       Date:  2014-06-27       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.